Contents Link Navigation Link
ABOUT US

Targeting, Attacking, Eradicating Cancer

Company History

Targeting, Attacking, Eradicating Cancer

2016
Dec.Sillajen is listed on KOSDAQ market in South Korea.

Jan.SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer.
markmarkmark
2015
Oct.SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products".
markmark
2015
Apr.SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer.
mark
2014
Mar.SillaJen acquires Jennerex, Inc., the global leader in oncolytic immunotherapeutics.
mark
2013
May.US FDA designated Pexa-Vec as an orphan drug.
mark
2011
Jun.Jennerex initiated Pexa-Vec Phase 2b clinical trial (HEP018) for Liver Cancer.
markmark
2009
Nov.European Medicines Agency (EMA) designated Pexa-Vec as an orphan drug for Live Cancer.
markmarkmark
2008
Aug.Jennerex initiated Pexa-Vec Phase 2a clinical trial (HEP007).
mark
2007
Aug.Jennerex completed Pexa-Vec Phase 1 clinical trial (HEP001).
markmark
2006
Mar.Sillajen, Inc. was established.
markmarkmark
2003
Nov.Jennerex, Inc. (San Francisco, USA) was established.
mark